Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open-Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects

NCT02735603 is registered in ClinicalTrials.gov with Orexigen Therapeutics, Inc as lead sponsor.

NCT NCT02735603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02735603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open-Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects
Lead sponsor
Orexigen Therapeutics, Inc
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2016
Completion date
October 31, 2016
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart repolarization